Vericel (VCEL) Amortizatization of Intangibles (2018 - 2026)
Vericel (VCEL) posted Amortizatization of Intangibles of $52000.0 for Q2 2026, up 92.59% sequentially from $27000.0 in Q1 2026, and down 1.89% YoY from $53000.0 in Q2 2025.
Analysis
Vericel (VCEL) Amortizatization of Intangibles (2018 - 2026) Analysis & Trends
Vericel has reported Amortizatization of Intangibles for 9 years, with the latest figure at $52000.0 in Q2 2026.
- Quarterly Amortizatization of Intangibles fell 1.89% year-over-year to $52000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $90000.0 (down 80.6% YoY) and the FY2025 annual result came in at $183000.0, down 72.15% from the prior year.
- Amortizatization of Intangibles improved to $52000.0 in Q2 2026 per VCEL's latest filing, from $27000.0 in the prior quarter.
- Over five years, Amortizatization of Intangibles peaked at $290000.0 in Q1 2023 and troughed at -$194000.0 in Q1 2022.
- A 5-year average of $90888.9 and a median of $86000.0 in 2024 frame the typical range for Amortizatization of Intangibles.
- The sharpest annual moves came in 2023 and 2025: Amortizatization of Intangibles soared 9566.67% in 2023, then plunged 151.3% in 2025.
- Over 5 years, Amortizatization of Intangibles stood at $198000.0 in 2022, then slumped by 81.82% to $36000.0 in 2023, then surged by 219.44% to $115000.0 in 2024, then slumped by 151.3% to -$59000.0 in 2025, then jumped by 188.14% to $52000.0 in 2026.
- According to Business Quant data, Amortizatization of Intangibles over the past three periods registered $52000.0, $27000.0, and -$59000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 4.33 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 678,000.00 |
| 10 | Vericel | 2.05 Bn | 1.89 Bn | 56.40 Mn | 1.40 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.40 Mn |
| Mar 31, 2026 | 1.37 Mn |
| Dec 31, 2025 | 1.34 Mn |
| Sep 30, 2025 | 1.31 Mn |
| Jun 30, 2025 | 1.32 Mn |
| Mar 31, 2025 | 1.38 Mn |
| Dec 31, 2024 | 1.51 Mn |
| Sep 30, 2024 | 1.66 Mn |
| Jun 30, 2024 | 1.71 Mn |
| Mar 31, 2024 | 1.77 Mn |
| Dec 31, 2023 | 1.78 Mn |
| Sep 30, 2023 | 1.83 Mn |
| Jun 30, 2023 | 1.35 Mn |
| Mar 31, 2023 | 1.11 Mn |
| Dec 31, 2022 | 1.10 Mn |
| Sep 30, 2022 | 965,000.00 |
| Jun 30, 2022 | 1.08 Mn |
| Mar 31, 2022 | 1.08 Mn |
| Dec 31, 2021 | 1.00 Mn |
| Sep 30, 2021 | 1.10 Mn |